Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)

Palinggi, Emmy; Palinrungi, Muhammad Asykar; Palinrungi, Achmad M.; Seweng, Arifin; Kholis, Khoirul; Syahrir, Syakri; Syarif, Syarif; Faruk, Muhammad

doi:10.5455/jmas.113358

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pooled results of three RCTs ( Abdelaziz et al, 2022 ; Jaworski et al, 2021 ; Palinggi et al, 2020 ) displayed no significant differences in all domain scores of the USSQ between the two groups at a two-week visit. Among them, two RCTs also reported the QoL score.…”

Section: Discussionmentioning

confidence: 88%

“…Lower urinary symptoms, higher satisfaction, and fewer Frontiers in Pharmacology frontiersin.org side effects may significantly decrease the general health score of the mirabegron group. The pooled results of three RCTs (Abdelaziz et al, 2022;Jaworski et al, 2021;Palinggi et al, 2020) displayed no significant differences in all domain scores of the USSQ between the two groups at a two-week visit. Among them, two RCTs also reported the QoL score.…”

Section: Discussionmentioning

confidence: 94%

“…We finally identified five RCTs ( Palinggi et al, 2020 ; Sahin et al, 2020 ; Jaworski et al, 2021 ; Abdelaziz et al, 2022 ; Chandna et al, 2022 ) in this meta-analysis through database search: three RCTs compared the effects of mirabegron and solifenacin ( Palinggi et al, 2020 ; Abdelaziz et al, 2022 ; Chandna et al, 2022 ); one compared the effects of mirabegron and oxybutynin ( Jaworski et al, 2021 ); and another compared the effects of mirabegron and a combination of solifenacin and tamsulosin ( Sahin et al, 2020 ). Table 1 lists the primary characteristics of the included studies.…”

Section: Resultsmentioning

confidence: 99%

“…Four RCTs ( Palinggi et al, 2020 ; Jaworski et al, 2021 ; Abdelaziz et al, 2022 ; Chandna et al, 2022 ) designed multiple follow-up visits on the USSQ to study SRSs. The measured time point of the questionnaire ranged from 3 days to 6 weeks.…”

Section: Resultsmentioning

confidence: 99%

“…Three studies ( Palinggi et al, 2020 ; Jaworski et al, 2021 ; Chandna et al, 2022 ) that enrolled 171 participants (85 in the mirabegron group and 86 in the antimuscarinics group) analyzed the USSQ at week 1. A fixed effects model revealed that mirabegron significantly reduced urinary symptoms (MD −1.39, 95% CI −2.63 to −0.15, p = 0.03) and improved general health (MD −1.65, 95% CI −2.60 to −0.69, p = 0.0007) ( Figures 3A, C ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Lu,

Li,

Zou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs).Methods: All randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Web of Science, and Cochrane Library. The RevMan version 5.3.0 software was used for statistical analysis.Results: This meta-analysis included five RCTs involving 317 patients. A fixed effects model revealed that mirabegron was superior to antimuscarinics in treating urinary symptoms (MD −1.39, 95% CI −2.63 to −0.15, p = 0.03) and general health (MD −1.65, 95% CI −2.60 to −0.69, p = 0.0007) 1 week after treatment initiation. We observed no significant differences in body pain (MD 0.05, 95% CI −1.06 to 1.15, p = 0.94), work performance (MD −0.86, 95% CI −1.77 to 0.06, p = 0.07), and sexual matters (MD 0.03, 95% CI −0.77 to 0.83, p = 0.94). Two weeks after treatment initiation, the ureteral stent symptom questionnaire (USSQ) revealed no significant differences between the two groups. The mirabegron group demonstrated a significant improvement in the quality of life (QoL) (MD −0.18, 95% CI −0.34 to −0.01, p = 0.03), while the International Prostate Symptom Score did not reveal a significant difference between the two groups (MD −0.74, 95% CI −1.79 to 0.32, p = 0.17). Regarding safety, a pooled data analysis presented that the incidence of constipation was lower in the mirabegron group (OR 0.10, 95% CI 0.01 to 0.77, p = 0.03). The mirabegron and antimuscarinics groups did not differ significantly concerning the risk of dry mouth (OR 0.15, 95% CI 0.02 to 1.27, p = 0.08).Conclusion: Mirabegron is superior to antimuscarinics in alleviating ureteral SRSs and improving QoL. Additionally, mirabegron 50 mg/day presented safety with a lower incidence of constipation.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Lu,

Li,

Zou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis

Besien

Keller

Somani

et al. 2022

European Urology Focus

View full text Add to dashboard Cite

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Elmarakbi,

Elsayed,

Mohamed

et al. 2024

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

Background Inserting ureteral stents is a routine intervention that often results in problems. The cornerstone for treating stent-related symptoms is pharmacological therapy. This study was conducted to evaluate and to compare the effectiveness of mirabegron, tamsulosin, solifenacin and control in reducing double-J stent-related symptoms. Results Patients were evaluated preoperatively, one week after stent insertion and two weeks after the start of medications by the Ureteral Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS), overactive bladder questionnaire (OAB-q) and visual analogue pain scale (VAPS). Solifenacin and mirabegron groups had significantly lower sexual scores after the 1st and 2nd weeks post-operatively (PO) when compared with the control group. Mirabegron group had significantly lower sexual scores after 1st and 2nd weeks PO when compared with patients in tamsulosin and solifenacin groups. Patients in mirabegron group had significantly fewer additional problems after the 1st and 2nd weeks PO when compared with patients in the control and tamsulosin groups. Conclusions To sum up, mirabegron was found to be superior to solifenacin in lowering urinary symptoms scores, sexual performance scores and work performance scores at both first and second weeks post-operatively. Mirabegron is a good alternative choice for SRSs when tamsulosin or solifenacin is ineffective or not tolerated.

show abstract

Effectiveness of using Solifenacin compared to Mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)

Cited by 4 publications

References 0 publications

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Contact Info

Product

Resources

About